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INTRODUCTION 
Today, there is an increased demand for the pharmacy profession and curricula to focus on the 
development of patient care skills, with emphasis on patient-centered care. The Accreditation 
Council for Pharmacy Education (ACPE) Guidance of Standards 2016 recommends pharmacy 
curricula to incorporate self-directed, active learning strategies to facilitate learning experiences 
and improve learning outcomes.1 To address this recommendation in the pharmacy curricula, 
virtual human (VH) patient simulation has been used to teach chronic disease management,2 
assess learner core competencies prior to Advanced Pharmacy Practice Experiences (APPE),3 
and promote self-directed learning with various disease states, such as postoperative nausea and 
vomiting and anemia of chronic kidney disease.4  
 
For the purpose of this study, VH simulation can be defined as a “computer-generated three-
dimensional (3-D) model that simulates real-life clinical scenarios and patient encounters”.5 VH 
simulation has many functional layers. With artificial intelligence (AI) and natural language 
processes,  simulation can provide a platform to develop interpersonal skills with virtual patients 
that can be translated into highly effective patient-provider interaction with real patients.6 VH 
Objective. To acquire clinical data on pain management and opioid use disorder in order to 
provide the relevant artificial intelligence content and foundation to help develop a virtual 
human patient simulation model. 
Methods. A systematized search of the PubMed database was conducted using search 
terms related to opioid drugs and psychological and behavioral processes. A stepwise 
approach was used to refine and limit search terms and keywords based on the number of 
results returned. Resulting articles were extracted and used to derive “if-then rules” that 
reflect each psychological or behavioral change influenced by opioid use.  
Results. A search from January 2017 to February 2018 identified 62 full-text articles that 
were included in the literature review. 273 “if-then rules” were derived, with 247 focusing on 
psychological processes and 26 focusing on behavioral processes. A number of studies 
involved methadone (33.9%), multiple opioids (24.2%), and buprenorphine (22.6%). Opioid 
dependence was reported in 41.9% of the studies. 
Conclusion. This literature review supports the rising interest in opioid replacement therapy, 
most notably in methadone and buprenorphine, in light of the U.S. opioid epidemic in recent 
years. Additional research is needed to focus on the effects of opioids on behavioral 
processes. 
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simulation enables learners to take on the roles of healthcare providers to obtain a medical history, 
conduct a physical exam, and make diagnostic and therapeutic decisions.7 By repeatedly 
exposing learners to an extensive list of clinical variation, some researchers argued that VH 
simulation can help reinforce core knowledge and foster clinical reasoning processes to help 
learners to consider alternative options, reflect on a case’s objectives, and contrast with other 
cases.8 With the recent advances in educational technologies and rapidly changing landscape of 
health education, simulation represents a unique opportunity to teach and train tomorrow’s health 
professionals. Considering that nearly all schools and colleges of pharmacy in the U.S. reported 
using some type of educational technology in 2011, it can be proposed that the use of VH 
simulation is an especially important consideration for the field of pharmacy and pharmacy 
education.9  
 
This current study is a component of a larger study focused on developing a VH simulation to 
teach and train in pain management. To our knowledge, there is limited use of VH simulation in 
pharmacy education that targets pain management, with emphasis on opioid use disorder. 
Opioids are a class of natural and synthetic chemicals that are frequently prescribed to help 
alleviate moderate-to-severe pain associated with medical disease or condition, injury, or medical 
treatment. Although the benefits of opioids outweigh the risks with intended use, the misuse and 
abuse of these medications often predispose patients to more serious risks, such as physical 
dependence and overdose.10 In 2013, the overall healthcare cost of prescription opioid overdose, 
abuse, and dependence was estimated to exceed $78.5 billion per year.10 In 2014, approximately 
2 million Americans reported dependence or abuse of prescription opioids.11 Today, the opioid 
epidemic remains one of the most prevailing healthcare issues facing the U.S. According to the 
CDC, 115 Americans die from opioid overdose every day.11 Although patients with a history of 
mental illness and drug abuse are more vulnerable to develop opioid abuse, the risk of opioid 
overdose is not limited to patient factors. Since the 1990s, there has been a rapid increase in 
opioid prescriptions due to the lack of adequate pain management in certain patient populations, 
including females, elderly, and patients with cancer pain.12 Pain management changes in the 
1990s gave rise to ongoing high-risk prescribing practices in the 2000s, such as high-dose 
prescribing and overlapping prescriptions from multiple providers. In 2013, healthcare providers 
prescribed approximately a quarter of a billion opioid medications – enough medications for every 
adult to have his or her own bottle of pills.11 In March 2016, as an acknowledgement to the 
provider’s role in the opioid overdose epidemic, the CDC released its Guideline for Prescribing 
Opioids for Chronic Pain in order to address the concern of over-prescription. However, due to 
the subjective nature of pain, the prevention, assessment, and treatment of pain remains a major 
challenge for healthcare providers.11 
 
Pharmacists can serve on the forefront of helping to manage the opioid epidemic. As members 
of one of the most accessible health professionals, pharmacists can play an active role in 
identifying misuse and addressing abuse in the community. Thus, it is important for pharmacy 
learners to be exposed to the education and training on pain management and opioid use disorder 
early on in the pharmacy curriculum. VH simulation exists as one innovative technological solution 
that can provide learning opportunities for these learners. The simulated patient can capture and 
display pain expressions and behavioral characteristics for learner recognition. The simulated 
environment allows pharmacy learners to interact with a virtual patient with human characteristics 
and behaviors that mimic a real patient. In these scenarios, learners must learn how to gather 
pertinent information and cultivate the clinical reasoning skills necessary to identify and address 
concerns and risks of opioid use, including overdose, abuse, and dependence. With adequate 
education and training, learners can then transfer knowledge and apply clinical reasoning skills 
learned with the virtual patients to real-life encounters with patients.  
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To ensure that the AI underlying the current VH simulation is robust and comprehensive, the 
objective of this study was to conduct a literature review and perform data acquisition to provide 
the relevant AI background content and framework on pain management and opioid use disorder. 
METHODS 
A systematized search of literature on the PubMed database was conducted from January 2017 
to February 2018 to determine the psychological and behavioral impacts of opioid use on patients 
with pain. Since this was a literature review of published data, no approval was required from the 
University’s Institutional Review Board. Initially, a list of search terms created by PubMed’s 
Medical Subject Headings (MeSH) database included 47 opioid drugs and three specific 
keywords: opioids, opiate, and opiates. To generate a more tractable set of studies while 
maintaining breadth, the list was narrowed down to 11 common opioid drugs in the United States: 
buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, 
morphine, oxycodone, oxymorphone, and tramadol. To support the VH simulation, and in 
particular, the AI necessary to guide the VH patient’s behaviors, the primary endpoint was to 
identify five psychological and five behavioral processes to be used as search terms. After 
considering common topics presented in the behavioral sciences literature, the following 10 
search terms were combined with the list of opioid drugs and keywords: interpersonal, memory, 
attention, arousal, decision-making, facial expression, posture, gesture, body language, and eye 
contact.13 Any search term that yielded too many results was subdivided into more specialized 
terms. To be included in the review, studies must have been full-text articles published in English 
and have described, regardless of methodology, the psychological or behavioral impacts of opioid 
use on human patients with pain. Initially, search results were limited to studies that were 
published in the past five years. For search terms with too few results, the inclusion criterion was 
extended first to studies published in the past 10 years, then to studies published from any year. 
 
One reviewer (HL) scanned the titles of all studies. Studies were excluded if their titles focused 
on the opioid pharmacology, pharmacokinetics, or pharmacodynamics. Studies were also 
excluded if their titles focused on opioid use disorder epidemiology. If the first reviewer felt that 
the title was potentially eligible for inclusion, as needed in consultation with the second author 
(RH), then the abstract was screened. Following this, the reviewer read the full-text article to 
determine if the study met the inclusion criteria. Studies were excluded if they included non-adult 
patients, current heroin users, or prescribers’ perspective on opioid use disorder, as these details 
were not expected to be useful for generating AI for the current VH simulation. Studies were also 
excluded if they included opioid use for unrelated indications (ephdrone-induced Parkinsonism), 
or use of unrelated drugs (oxytocin, ketamine, etoricoxib, topical morphine) for pain management. 
Additional studies were screened for inclusion by searching the reference lists of relevant 
literature identified in these searches.  
 
The following data were collected from all included studies: first author, year, study location, study 
design, sample size, mean age of participants, sex of participants, opioids studied, type of pain 
studied (chronic versus acute), and the presence of opioid dependence (yes versus no). 
Furthermore, data from all included studies were extracted to yield relevant methods, summarized 
results, and overall implications regarding the psychological and behavioral impacts of opioid use. 
The secondary endpoint was to generate “if-then rules” by analyzing data extracted from the 
literature. An “if-then rule” is a form of specification for AI in which a set of actions (then 
statements) can be performed when one or more conditions (if statements) are satisfied.14 Figure 
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1 illustrates an example of an “if-then rule.” The “if-then rules” that derived from the current study 
could be translated into codes and incorporated into the AI language of the VH simulation by a 
separate team of computer programmers. 
 
 
RESULTS 
The selection of studies for the systematized literature review is shown in Figure 2. Initial literature 
searches identified 1102 studies; further investigation identified a need to subdivide the search 
term attention (n = 412) into more specific keywords: divided attention (n = 7) and selective 
attention (n = 8). Upon including 11 articles searched through reference lists of included studies, 
716 studies were identified to be screened. After title scans, 133 studies remained. The abstracts 
were assessed for potential eligibility. A total of 62 full-text articles were included in the 
systematized review, including 55 studies related to psychological processes and seven studies 
related to behavioral processes. 
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The characteristics of the studies included in the systematized review are shown in Table 1. Most 
studies were published between 2000 and 2018 (n = 60). The oldest study was published in 1983. 
A total of 34 studies were conducted in North America (54.8%), including 28 studies in the United 
States (45.2%). A number of studies were also conducted on the following continents: 14 studies 
in Europe, 7 studies in Australia, 3 studies in Africa, 3 studies in Asia, and 1 study in multiple 
countries. With regards to study design, the majority of the studies were either controlled trial 
studies (37.1%) or comparative studies (35.5%). There was a total of nine qualitative interviews, 
and 88.9% of the interviews were conducted to assess decision-making processes with opioid 
use (Table 1). The remaining studies were conducted as meta-analyses (n = 4), case control 
studies (n = 2), and retrospective analyses (n = 2). Excluding the meta-analyses (n = 4), most 
studies had small sample sizes of less than 50 patients (58.6%). Thirteen studies had patient 
sample sizes of 50 to 100 and 11 studies had patient sample sizes of more than 100. Most studies 
included patients in the following range of ages: 33 studies included patients with mean ages 
between 20 and 39 years and 21 studies included patients with mean ages between 40 and 59 
years old. One study included patients with a mean age of 65.2 years old23, 2 studies included 
patients with mean ages between 29 and 84 years old, and 5 studies did not report the mean age. 
Nine studies had the same percentage of male and female patients included in the studies. A 
number of studies had more male patients (n = 24), more female patients (n = 23), or did not 
report sex percentages (n = 6). 
 
Table 1. Characteristics of studies included in literature review 
First author (Year) Study location Study design 
Sample size 
(no. of patients) 
Interpersonal    
Xia (2013)16 China Qualitative interviews 27 
Inagaki (2015)17 USA Controlled trial 31 
Sun (2015)18 China Meta-analysis 38 studies 
Bershad (2016)19 USA Controlled trial 36 
Burgdorf (2016)20 Germany Controlled trial 48 
Inagaki (2016)21 USA Controlled trial 31 
Bershad (2018)22 USA Controlled trial 38 
Memory    
Kamboj (2005)23 UK Comparative 14 
Darke (2012)24 Australia Case Control  225 
Anderson (2013)25 USA Controlled trial 34 
Gandolphe (2013)26 France Comparative 110 
McDonald (2013)27 Australia Case Control  225 
Kamboj (2014)28 UK Controlled trial 20 
Schiltenwolf (2014)29 Germany Comparative 95 
Spierings (2014)30 USA Controlled trial 30 
Terrett (2014)31 Australia Comparative 56 
Kurita (2015)32 Denmark Controlled trial 22 
Mercuri (2015)33 Australia Comparative 96 
Rass (2015)34 USA Controlled trial 56 
Syal (2015)35 South Africa Controlled trial 38 
Bell (2016)36 USA Comparative 48 
Bassiony (2017)37 Egypt Comparative 100 
Attention, Divided    
Hill (2000)38 USA Controlled trial 17 
Zacny (2003)39 USA Controlled trial 18 
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Zacny (2005)40 USA Controlled trial 18 
Walsh (2008)41 USA Controlled trial 9 
Zacny & Gutierrez (2008)42 USA Controlled trial 16 
Zacny & Lichtor (2008)43 USA Controlled trial 20 
Sproule (2009)44 
USA Retrospective 
analysis 
428 
Zacny (2009)45 USA Controlled trial 20 
Mintzer (2010)46 USA Controlled trial 9 
Schoedel (2010)47 Canada Controlled trial 35 
Henry (2012)48 USA Comparative 77 
Mailis-Gagnon (2012)49 Canada Meta-analysis 35 studies 
Rass (2014)50 USA Comparative 51 
Attention, Selective    
Pirastu (2006)51 Italy Comparative 69 
Rapeli (2007)52 Finland Comparative 50 
Soyka (2008)53 Germany Controlled trial 70 
Nejati (2011)54 Iran Comparative 60 
Bracken (2012)55 USA Comparative 35 
Arousal    
David (2013)56 Multiple countries Meta-analysis 8 studies 
Garland (2013)57 USA Comparative 65 
Ajo (2016)58 Spain Comparative 263 
Smith (2016)59 
USA Retrospective 
analysis 
34,566 
Wardle (2016)60 USA Comparative 34 
Decision-Making    
Vallerand (2009)61 USA Qualitative interviews 22 
Vallerand (2010)62 USA Qualitative interviews 22 
Esquibel (2014)63 USA Qualitative interviews 21 
Brooks (2015)64 Nova Scotia Qualitative interviews 9 
McCrorie (2015)65 UK Qualitative interviews 23 
Smith (2015)66 USA Qualitative interviews 23 
Biernacki (2016)67 Australia Meta-analysis 22 studies 
Paterson (2016)68 Australia Qualitative interviews 20 
Yarborough (2016)69 USA Qualitative interviews 283 
Garami (2017)70 Australia Comparative 183 
Facial Expression    
Hadjistavropoulos (1994)71 Canada Comparative 90 
Kornreich (2003)72 Belgium Comparative 150 
Martin (2006)73 UK Comparative 61 
Carroll (2011)74 UK Comparative 20 
Ipser (2013)75 South Africa Controlled trial 20 
Posture    
Rubin (1983)76 USA Controlled trial 16 
Fan (2012)77 Canada Comparative 223 
 
The number of studies and “if-then rules” corresponding to each psychological or behavioral 
process are shown in Table 2 and 3, respectively. A total of 273 rules were derived from relevant 
literature, including 247 rules related to psychological processes and 26 rules related to 
behavioral processes. 
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Table 2. Summary of literature and rules related to psychological processes 
Psychological processes No. of studies No. of rules 
Interpersonal 7 17 
Memory 15 56 
Attention   
Attention, Divided 13 61 
Attention, Selective 5 18 
Arousal 5 27 
Decision-Making 10 68 
Total 55 247 
 
Table 3. Summary of literature and rules related to behavioral processes 
Behavioral processes No. of studies No. of rules 
Facial Expression 5 22 
Posture 2 4 
Gesture 0 0 
Body Language 0 0 
Eye Contact 0 0 
Total 7 26 
 
A number of studies involved methadone (33.9%), multiple opioids (24.2%), and buprenorphine 
(22.6%). There was an equal number of studies focusing on patients with chronic pain (n = 17) 
and healthy volunteers with no pain (n = 17). Twenty-six studies involved opioid-abusing patients 
with no pain and two studies involved patients with acute pain. Opioid dependence was reported 
in 41.9% of the studies. A number of studies did not include patients with opioid dependence (n 
= 23) or did not report presence of opioid dependence (n = 13). 
 
Table 4. Number of studies and rules, by opioids studied 
Opioids studied No. of studies No. of rules 
Buprenorphine 14 57 
Buprenorphine/Naloxone 4 22 
Hydrocodone 3 27 
Hydromorphone 2 8 
Methadone 21 89 
Morphine 8 35 
Naltrexone 5 10 
Oxycodone 4 34 
Oxymorphone 2 4 
Tramadol 2 6 
Multiple Opioidsa 15 92 
Otherb 4 9 
aNot included in the studies or rules for individual opioid listed 
bOpioids with one resulting article (DAMME, remifentanil, naloxone, no opioids)  
 
 
 
 
 9 
Table 5. Number of studies and rules, by type of pain 
Type of pain No. of studies No. of rules 
Acute pain 2 11 
Chronic pain 17 92 
Opioid abusers (no pain) 26 106 
Healthy volunteers (no pain) 17 66 
Not reported 1 1 
 
Table 6. Number of studies and rules, by presence of opioid dependence 
Opioid Dependence No. of studies No. of if-then rules 
Yes 26 106 
No 23 93 
Not reported 13 74 
DISCUSSION 
This systematized literature review is the first study to provide the clinical knowledge of pain 
management and opioid use disorder necessary to help develop a VH simulation. We derived a 
total of 273 “if-then rules” to be programmed into the AI language underlying the VH simulation. 
Approximately 90.5% of those “rules” can be attributed to the effects of opioids on psychological 
processes. The small number of articles found in this literature review that focus on behavioral 
characteristics suggests that there are research needs in this area, particularly studies that 
evaluate the impact of opioid use on gesture, body language, and eye contact, since these 
behaviors may be informative to a pharmacist. 
 
This literature search found a number of articles focused on methadone and buprenorphine (21 
and 14 studies, respectively). Methadone and buprenorphine are part of medication-assisted 
treatments (MAT), which combines opioid treatment programs (OTPs) with behavioral therapy to 
treat opioid use disorder and addiction.78 Methadone, an opioid agonist, and buprenorphine, a 
partial opioid agonist, are commonly used to help relieve withdrawal symptoms for opioid-
dependent patients as part of the detoxification process. Since most articles (96.8%) found in our 
literature review were published within the last 18 years, the number of articles found for these 
drugs suggests that there has been a recent increase in interest and research in opioid 
replacement therapy within the last few years. This finding is not surprising, as our healthcare and 
federal government has shifted its focus to opioid detoxification within the recent years in light of 
the U.S. opioid epidemic. According to the Substance Abuse and Mental Health Service 
Administration (SAMHSA), both the number of patients receiving methadone and buprenorphine 
increased from 227,003 and 727, respectively, in 2003 and 2004, to 356,842 and 21,628 in 2015, 
respectively.78 In fact, the percentage of OTPs with buprenorphine increased from 11% in 2003 
to 58% in 2015, and approximately 21-25% of all patients who receive substance abuse treatment 
each year are patients who receive methadone as part of their MAT.78 In the state policy arena, 
Burns et al reported that there has been an increase in Medicaid coverage of both methadone 
and buprenorphine from 21 states in 2004 to 32 states in 2013.79 Despite increasing data on its 
efficacy and cost-effectiveness, further research on methadone and buprenorphine is necessary 
to prompt the remaining state Medicaid to grant coverage.  
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In this literature search, the 24.2% of articles that constitute “multiple opioids” fall into the study 
design categories of meta-analyses, retrospective analyses, and qualitative interviews, in which 
the studies assessed overall patient experience with any opioid rather than with individual opioid. 
This literature review suggests there is a gap in literature studying the effects of other opioids 
drugs, such as hydromorphone, oxymorphone, and tramadol, on psychological and behavioral 
characteristics. 
 
Twenty-six articles studying opioid abusers (Table 5) are consistent with the number of articles 
studying methadone and buprenorphine (Table 4). A strength of this study is the equal number of 
articles studying effect of opioids on patients with chronic pain and healthy volunteers (Table 5). 
The results of this literature review also show proportional representation between opioid-
dependent and non-opioid-dependent patients (Table 6). Initially, we intended to search for 
research articles on prescription drug abuse. One limitation of this current study is that we did not 
exclude heroin from our search terms. As a result, many of the articles we found focused on 
heroin abusers, rather than prescription drug abusers. Related research in the future should 
establish more well-defined exclusion criteria. Furthermore, additional research in the future 
should utilize multidisciplinary healthcare providers to help review and evaluate the clinical 
relevance of literature findings. Pain specialists can also contribute clinical knowledge to support 
the development of educational contents that may not have been studied or addressed in the 
primary literature. In addition, the integrative expert opinions and clinical experiences of the team 
can help fill in the literature gaps surrounding behavioral characteristics and provide a more 
comprehensive understanding of pain management and opioid use disorder. 
CONCLUSION 
The development of VH simulation can provide an innovative way to transform the teaching, 
learning, and practice of clinical healthcare. VH simulation can capture and display pain 
expressions and characteristics for learner recognition and present realistic cases to learners to 
encourage active learning. In addition, VH simulation can simulate clinical scenarios of opioid 
overdose, abuse, and dependence, which can help learners develop the clinical reasoning skills 
necessary to address concerns and risks of opioid use in a virtual setting. The rationale to develop 
a VH opioid patient simulation in the pharmacy curricula lies in the role that pharmacists can play 
due to the continued rise of opioid overdose deaths in the U.S.11 As members of one of the most 
accessible health professionals, pharmacists are in a unique position to identify at-risk patients 
for opioid use disorder and prevent opioid overdose, misuse, and abuse in the community.  
Although the use of VH simulation has been explored in health education, the specific 
technological platform that will utilize the “if-then rules” derived from this study is intended to 
dramatically improve education and training in patient-centered care in the pharmacy curriculum. 
The impact of this study lies in the education and learning of future health providers, particularly 
pharmacists. The continuing impact of this study may extend beyond healthcare education to the 
development of healthcare policies that may shape the management of the U.S. opioid epidemic 
in the future. 
 
In this systematized literature review, more than 270 “if-then rules” that reflect psychological and 
behavioral effects of opioids were derived to support the development of a VH patient simulation. 
A number of articles focusing on the effects of methadone and buprenorphine support the 
increasing research and interest in opioid replacement therapy within the recent years due to the 
U.S. opioid epidemic. Gaps in the literature and future research needs focusing on behavioral 
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effects of opioids were identified in this literature search. Similar studies in the future should 
determine more well-defined exclusion criteria with the focus on prescription drug abuse. 
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